https://charts.traderzeitung.de/phases/US60770K1079
string(1467) "{"isin":"US60770K1079","name":"Moderna Inc","stock_id_xnas":7874441,"stock_id_xnys":null,"generated_at":"2026-07-21 12:26:00","days":[{"date":"2026-07-17","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":61.66,"close_at":"2026-07-17 15:27:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":61.805,"close_at":"2026-07-17 21:59:00","complete":true,"perf_pct":0.2352},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":61.73,"close_at":"2026-07-17 23:59:00","complete":true,"perf_pct":-0.1213}]},{"date":"2026-07-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":61.44,"close_at":"2026-07-20 15:28:00","complete":true,"perf_pct":-0.4698},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":59.51,"close_at":"2026-07-20 21:59:00","complete":true,"perf_pct":-3.1413},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":59.51,"close_at":"2026-07-20 23:32:00","complete":true,"perf_pct":0}]},{"date":"2026-07-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":59.73,"close_at":"2026-07-21 11:14:00","complete":false,"perf_pct":0.3697},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Moderna Aktie News & Nachrichten

Moderna Aktie News & Nachrichten

[WKN: A2N9D9 | Symbol: MRNA]
Realtimekurs
   

Moderna: Der CEO kauft für 5 Mio. USD Aktien. Bis 2027 sollen zehn neue Produkte auf den Markt kommen. Rebound-Chance!

Läuft es bei Moderna (MRNA) im Hintergrund gar nicht schlecht? Der Aktienkurs lässt mit seinem Dauerabsturz...

Moderna: Mehr als nur COVID-19

Moderna hat sich mit seinem mRNA-Impfstoff gegen COVID-19 einen Namen gemacht, doch das Unternehmen...

Moderna: Comeback dank KI? Laut Oracle-CEO Ellison könnten Krebs-Impfstoffe binnen 48 Stunden entwickelt werden.

Für den mRNA-Spezialisten Moderna (MRNA) war die Corona-Pandemie die große Zeit. Mit dem Abebben der...